Market Place
Sourcing Support
Adaptimmune`s cell therapy hits key goal in pivotal sarcoma test
13 Nov 2024 //
FIERCE BIOTECH
First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer
03 Aug 2024 //
PRESS RELEASE
Adaptimmune Prepares For Possible Approval Of Novel Engineered T Cell Therapy
29 Jul 2024 //
BIOSPACE
Adaptimmune Gears Up for Potential Approval of First-in-Class Engineered T Cell Therapy
29 Jul 2024 //
BIOSPACE
Adaptimmune’s debt financing deal; Tenaya to cut workers
15 May 2024 //
ENDPTS
Roche, Adaptimmune part ways on cell therapy research
13 Apr 2024 //
BIOPHARMADIVE
GSK pays out £30M to Adaptimmune as cell therapy work ends
11 Apr 2023 //
FIERCE BIOTECH
Adaptimmune & TCR² Announce Combination to Create Cell Therapy Company
06 Mar 2023 //
GLOBENEWSWIRE
Adaptimmune absorbs TCR² to extend cash runway, broaden pipeline
06 Mar 2023 //
FIERCE BIOTECH
Adaptimmune to lay off up to 30% of staff amid pipeline shift
08 Nov 2022 //
FIERCEBIOTECH
GSK axes Lyell cell therapy, passes programs to Adaptimmune
26 Oct 2022 //
FIERCEBIOTECH
GSK deals cell therapy another setback
25 Oct 2022 //
EVALUATE
Adaptimmune Reports Positive Data in its SURPASS Trial
09 Sep 2022 //
ADAPTIMMUNE
Adaptimmune touts new PhI data for its cell therapy treatment
09 Sep 2022 //
ENDPTS
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
04 May 2022 //
GLOBENEWSWIRE
Adaptimmune to Report Q1 2022 Financial Results and Business Updates
28 Apr 2022 //
GLOBENEWSWIRE
Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Adaptimmune to Report Q4 and FY 2021 Financial Results
08 Mar 2022 //
GLOBENEWSWIRE
John Lunger, of Adaptimmune, Joins Genocea Bio` Board of Directors
07 Mar 2022 //
GLOBENEWSWIRE
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
26 Jan 2022 //
GLOBENEWSWIRE
Why Adaptimmune Therapeutics Stock Is Crashing Today
02 Dec 2021 //
NASDAQ
Adaptimmune`s T-cell therapy clears efficacy bar in solid tumors
13 Nov 2021 //
FIERCEBIOTECH
Adaptimmune says it`s (nearly) ready to head to the FDA with TCR cancer therapy
12 Nov 2021 //
ENDPTS
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial at CTOS
11 Nov 2021 //
GLOBENEWSWIRE
Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings
05 Oct 2021 //
GLOBENEWSWIRE
Why Adaptimmune Therapeutics Was Sinking This Week
17 Sep 2021 //
FOOL
Roche inks $3B biobucks deal for Adaptimmune`s T cells
08 Sep 2021 //
FIERCEBIOTECH
Adaptimmune Updates Data from its PI Trial for Liver Cancer at ILCA
05 Sep 2021 //
GLOBENEWSWIRE
Adaptimmune Updates Data from its PI Trial for Liver Cancer at ILCA
05 Sep 2021 //
GLOBENEWSWIRE
Adaptimmune Q2 2021 Financial Result and Business Monday, August 9, 2021
28 Jul 2021 //
GLOBENEWSWIRE
ASCO: Adaptimmune’s cell therapy shrinks 39% of rare sarcomas
18 May 2021 //
FIERCEBIOTECH
Adaptimmune to Present First Preclinical Data from its HLA-independent TCR HiT
27 Apr 2021 //
GLOBENEWSWIRE
Adaptimmune `ready for primetime` as it prepares to launch T cell therapy
13 Jan 2021 //
ENDPTS
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS
15 Oct 2020 //
GLOBENEWSWIRE
PRIME status for Adaptimmune`s synovial sarcoma drug
28 Jul 2020 //
PHARMATIMES
PRIME status for Adaptimmune`s synovial sarcoma drug
27 Jul 2020 //
PHARMATIMES
Adaptimmune Granted Access to PRIM Regulatory Support by the EMA for ADP-A2M4
23 Jul 2020 //
GLOBENEWSWIRE
Positive Opinion for Orphan Drug Designation for ADP-A2M4
28 Apr 2020 //
GLOBENEWSWIRE
Adaptimmune`s ADP-A2M4 an Orphan Drug in Europe for soft tissue cancer
27 Apr 2020 //
SEEKINGALPHA
Astellas teams with Adaptimmune to create CAR-T, TCR therapies
15 Jan 2020 //
FIERCE BIOTECH
Leading National Health Plan Selects Inovalon’s Cloud-Based Pharmacy Platform
14 Jan 2020 //
GLOBE NESWWIRE
Astellas teams with Adaptimmune to create CAR-T, TCR therapies
13 Jan 2020 //
FIERCE BIOTECH
